Screener
AbCellera Biologics Inc. ABCL Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|
| Depreciation of property and equipment | 8,951 | 11,977 |
| Amortization of intangible assets | 1,851 | 1,851 |
| Amortization of operating lease right-of-use assets | 2,863 | 3,610 |
| Stock-based compensation | 28,993 | 24,299 |
| Other | 70 | 7,019 |
| Changes in operating assets and liabilities: | ||
| Research fees and grants receivable | (12,524) | 25,367 |
| Income taxes receivable | (7,588) | (8,024) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s stock-based comp?
- AbCellera Biologics Inc. (ABCL) reported stock-based comp of $12.29M in Q2 2026.
- How has AbCellera Biologics Inc.'s stock-based comp changed year-over-year?
- AbCellera Biologics Inc.'s stock-based comp decreased by 13.5% year-over-year, from $14.21M to $12.29M.
- What is the long-term trend for AbCellera Biologics Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $30.65M to $55.79M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about AbCellera Biologics Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude